Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes
November 4, 2019Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo
Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …
Current drugs are “poisoning” elderly patients due to insufficient trial data, House of Lords committee hears
November 1, 2019Medical Communications, Research and Development elderly patients, pharma, trial diversity
Elderly patients are being put at risk by prescriptions for drugs which have not been properly tested in their age …
England’s antibiotic use is down, but antibiotic-resistant infections still spreading, report warns
November 1, 2019Medical Communications, Research and Development Antibiotics, England, Review on antimicrobial resistance
A new report has revealed that GPs in England are writing fewer prescriptions for antibiotics, but this has done little …
Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region
November 1, 2019Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma
Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Transactions in the pharma sector: Through the EU merger review looking-glass
October 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing mergers, mergers and acquisitions, pharma
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population
October 31, 2019Research and Development AbbVie, Rinvoq, pharma
AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes
October 31, 2019Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure
Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
Genmab’s Executive VP and CFO to retire in 2020
October 31, 2019Research and Development Genmab, appointment, pharma
David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …
FDA committee votes to pull US approval for AMAG’s preterm birth drug Makena
October 31, 2019Sales and Marketing FDA, Makena, pharma
An FDA committee has passed a contentious vote recommending by a slim majority for the withdrawal of existing approval of …
The November 2019 issue of Pharmafocus is available to read for free online now!
October 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The latest monthly edition of Pharmafocus, the November issue, is available to read for free online now!
FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis
October 30, 2019Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma
The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
FDA slams brakes on trial for world’s most expensive drug following safety concerns in children
October 30, 2019Research and Development FDA, Novartis, Zolgensma, pharma
The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …
Expanded EU label for Benlyta now covers paediatric lupus patients
October 30, 2019Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma
GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis
October 30, 2019Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma
Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
GSK’s tuberculosis vaccine shows efficacy over three years in HIV negative patients
October 29, 2019Manufacturing and Production, Research and Development GSK, IAVI, Vaccine, pharma, tuberculosis
Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the …
Mylan issues recall for anxiety drug Xanax over contamination fears
October 29, 2019Manufacturing and Production Mylan, anxiety, pharma, xanax
Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
